Halozyme Therapeutics (HALO) Set to Post Quarterly Earnings on Thursday

Key Points

• Halozyme Therapeutics is expected to report Q3 2026 results after market close on November 5. Analysts project $2.30 in earnings per share and $490.85 million in revenue, compared with the company’s full-year EPS guidance of $8.65–$9.00.
• The company’s latest quarter exceeded expectations, with EPS of $2.28 versus the $1.79 consensus estimate and revenue of $481 million, up 47.7% year over year.
• HALO shares recently traded near their 52-week high, while analysts maintain a “Moderate Buy” consensus. However, insiders have sold 125,852 shares worth approximately $13.5 million over the past 90 days.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $2.30 per share and revenue of $490.85 million for the quarter. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Interested persons may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the company earned $1.54 EPS. The firm's quarterly revenue was up 47.7% compared to the same quarter last year. On average, analysts expect Halozyme Therapeutics to post $8.31 EPS for the current fiscal year and $9.79 EPS for the next fiscal year.

Halozyme Therapeutics Trading Up 1.2%

Shares of HALO opened at $130.03 on Thursday. Halozyme Therapeutics has a fifty-two week low of $61.22 and a fifty-two week high of $130.24. The business has a 50-day moving average of $112.74 and a 200 day moving average of $82.87. The firm has a market cap of $14.76 billion, a P/E ratio of 38.82, a price-to-earnings-growth ratio of 0.47 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on HALO shares. HC Wainwright increased their target price on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday, October 7th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, August 31st. Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. JPMorgan Chase & Co. upped their price target on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the company a "neutral" rating in a research note on Thursday, October 8th. Finally, TD Cowen upped their price target on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $99.55.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 18,996 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the transaction, the director owned 58,839 shares of the company's stock, valued at $6,339,313.86. The trade was a 24.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 125,852 shares of company stock valued at $13,538,046. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.